abrdn plc Has $43.95 Million Stock Holdings in BioNTech SE (NASDAQ:BNTX)

abrdn plc lifted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 70.7% during the fourth quarter, Holdings Channel reports. The firm owned 385,668 shares of the company’s stock after purchasing an additional 159,676 shares during the quarter. abrdn plc’s holdings in BioNTech were worth $43,947,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. GAMMA Investing LLC grew its holdings in shares of BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after buying an additional 111 shares in the last quarter. Perigon Wealth Management LLC grew its holdings in shares of BioNTech by 3.9% during the fourth quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company’s stock valued at $666,000 after buying an additional 224 shares in the last quarter. Atomi Financial Group Inc. grew its holdings in shares of BioNTech by 6.7% during the fourth quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company’s stock valued at $414,000 after buying an additional 229 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after buying an additional 388 shares in the last quarter. Finally, Planning Capital Management Corp grew its holdings in shares of BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after buying an additional 450 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Stock Up 4.5 %

Shares of BNTX opened at $122.38 on Thursday. The firm has a market capitalization of $29.34 billion, a price-to-earnings ratio of -58.28 and a beta of 0.17. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The business’s fifty day moving average price is $117.33 and its two-hundred day moving average price is $107.89. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same period last year, the company earned $0.73 EPS. On average, analysts predict that BioNTech SE will post -3.77 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on BNTX. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and boosted their target price for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. Berenberg Bank began coverage on BioNTech in a research note on Tuesday, November 19th. They issued a “buy” rating and a $130.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $150.00 price target on shares of BioNTech in a research report on Monday, November 18th. TD Cowen reduced their price target on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. Finally, Canaccord Genuity Group boosted their price target on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research report on Wednesday, November 27th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $142.72.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.